“This is a time that the science is mov­ing for­ward at a breath­tak­ing pace and re­veal­ing the molec­u­lar causes of dis­eases—rare dis­eases, com­mon dis­eases, ne­glected dis­eases, dis­eases of the de­vel­op­ing world—we’ve never been on such a fast course of dis­cove

Modern Healthcare - - Special Feature -

A fo­cus on re­search

pub­lic health agency,” she says. “We’re a science-based, science-driven reg­u­la­tory agency with a pub­lic health mis­sion.”

Ham­burg says she has tried to strengthen the FDA’s role in reg­u­lat­ing med­i­cal prod­ucts and food safety by re­cruit­ing ex­perts that can stay abreast of med­i­cal tech­nol­ogy that is in­creas­ingly com­plex and on which a grow­ing pro­por­tion of the pub­lic re­lies.

“And we also have to re­ally transform our­selves to op­er­ate in an in­creas­ingly glob­al­ized world,” Ham­burg says of ef­forts to ex­pe­dite the avail­abil­ity of med­i­cal in­no­va­tions de­vel­oped over­seas and to keep dan­ger­ous for­eign prod­ucts away from U.S. pa­tients.

An­other Wash­ing­ton physi­cian whose role was el­e­vated by the 2010 health­care law is Dr. Harvey Fineberg, pres­i­dent of the In­sti­tute of Medicine, who is ranked No. 8. His or­ga­ni­za­tion was au­tho­rized un­der the law to de­velop key rec­om­men­da­tions for the de­sign of the es­sen­tial ben­e­fits pack­age, or the com­po­nents of the var­i­ous in­surance poli­cies of­fered un­der the state in­surance mar­ket­places that the law will launch in 2014.

“It both de­fines what ev­ery­one should be en­ti­tled to re­ceive and also should help es­tab­lish stan­dards for de­cid­ing over time what is or is not in­cluded in an es­sen­tial ben­e­fits pack­age,” Fineberg says.

Even the Joint Com­mis­sion, an in­de­pen­dent, not-for-profit ac­cred­i­ta­tion and cer­ti­fi­ca­tion or­ga­ni­za­tion, saw sig­nif­i­cant ef­fects from the health­care law be­cause sev­eral com­po­nents have sim­i­lar goals as the Joint Com­mis­sion’s core mis­sion of re­duc­ing health­care fa­cil­i­ties’ com­pli­ca­tion and ac­ci­dent rates. Dr. Mark Chas­sin, pres­i­dent of the Joint Com­mis­sion, holds the No. 9 spot, down from No. 7 last year.

An ex­am­ple of Joint Com­mis­sion ef­forts that echo goals in the health­care law is its on­go­ing push for hos­pi­tals and other fa­cil­i­ties to adopt sim­ple ini­tia­tives that could have wide­spread com­pli­ca­tion-re­duc­tion im­pacts, such as hand-wash­ing.

“We’re help­ing hos­pi­tals and doc­tor’s of­fices to solve health and safety prob­lems whereas we only pre­vi­ously helped iden­tify those prob­lems,” Chas­sin says.

The com­mis­sion’s Cen­ter for Trans­form­ing Health­care also will par­tic­i­pate in the new pa­tient-safety ini­tia­tive by iden­ti­fy­ing and test­ing so­lu­tions for pre­vent­ing pa­tient in­juries, he says.

Dr. De­los “Toby” Cos­grove, pres­i­dent and CEO of the Cleve­land Clinic, rounded out the top-10 lead­ers. His or­ga­ni­za­tion also had a head­line-grab­bing role in de­vel­op­ment of

“This is a time that the science is mov­ing for­ward at a breath­tak­ing pace and re­veal­ing the molec­u­lar causes of dis­eases—rare dis­eases, com­mon dis­eases, ne­glected dis­eases, dis­eases of the de­vel­op­ing world—we’ve never been on such a fast course of dis­cov­ery as we are right now,” Collins says. “That is ex­hil­a­rat­ing to pre­side over and to try to nur­ture.”

The lat­est NIH fo­cus—and pos­si­bly one of the rea­sons its work is of par­tic­u­lar in­ter­est to this year’s 50 Most In­flu­en­tial vot­ers— is ef­forts to spur dis­sem­i­na­tion of med­i­cal re­search and de­vel­op­ment of clin­i­cal ap­pli­ca­tions faster than the av­er­age 17 years it takes most re­search to move into wide­spread clin­i­cal prac­tice.

Like many Wash­ing­ton of­fi­cials, Collins

“And that is not a par­ti­san state­ment but some­thing that has been agreed upon by peo­ple of all po­lit­i­cal per­sua­sions,” Collins says.

Dr. Mar­garet Ham­burg, com­mis­sioner of the Food and Drug Ad­min­is­tra­tion, also is among the top 10, al­though she fell from No. 2 last year to No. 7 in this year’s rank­ing. But that’s cer­tainly not be­cause the role of her agency has di­min­ished.

“FDA is a hugely im­por­tant and unique

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.